ArticleScientific reports2025
Correlation of rivaroxaban solubility in mixed solvents for optimization of solubility using machine learning analysis and validation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development of several machine learning based models for determination of small molecule pharmaceutical solubility in binary solvents at different temperatures.Scientific reports · 2025Article
- Combination of machine learning and Raman spectroscopy for prediction of drug release in targeted drug delivery formulations.Scientific reports · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, the solubility of rivaroxaban, a poorly water-soluble drug, was investigated in mixed solvent systems to address challenges in pharmaceutical formulation and bioavailability enhancement. Solubility optimization is essential for the effective delivery and therapeutic performance of rivaroxaban, as its low aqueous solubility limits oral bioavailability and necessitates innovative approaches for drug formulation. The study explored the role of primary alcohols combined with dichloromethane in improving solubility, emphasizing their industrial relevance in crystallization, purification, and drug manufacturing processes. To complement experimental insights, machine learning models were employed to predict rivaroxaban solubility based on temperature, solvent type, and mass fraction of dichloromethane. Three models-AdaBoost Gaussian process regression (ADAGPR), AdaBoost multilayer perceptron (ADAMLP), and AdaBoost LASSO regression (ADALASSO)-were evaluated using [Formula: see text], RMSE, and MAPE metrics. Among these, ADAGPR demonstrated superior performance with an R² score of [Formula: see text], outperforming ADAMLP [Formula: see text] and [Formula: see text]. It also achieved the lowest total RMSE [Formula: see text] and MAPE [Formula: see text], confirming its predictive precision and reliability. Optimal solubility conditions were identified at [Formula: see text] with a mass fraction of 0.8190 in a dichloromethane-methanol mixture, yielding a predicted solubility of [Formula: see text]. These findings highlight the potential of combining chemical engineering principles with advanced predictive modeling to optimize solubility in complex solvent systems, offering significant value to pharmaceutical development and process optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.